Search results
Results from the Tech24 Deals Content Network
Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss, U.S. Food and Drug Administration. Accessed August 9, 2024. Accessed August 9, 2024.
Semaglutide is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. [19] [20] [21] It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. [22] [23] It can be administered by subcutaneous injection or taken orally.
Hyperosmolar hyperglycemic state ( HHS ), also known as hyperosmolar non-ketotic state ( HONK ), is a complication of diabetes mellitus in which high blood sugar results in high osmolarity without significant ketoacidosis. [ 4][ 5] Symptoms include signs of dehydration, weakness, leg cramps, vision problems, and an altered level of ...
392 million (2015) [ 11] Type 2 diabetes ( T2D ), formerly known as adult-onset diabetes, is a form of diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. [ 6] Common symptoms include increased thirst, frequent urination, fatigue and unexplained weight loss. [ 3]
Popular weight-loss and diabetes medications linked to lower risk of some cancers, study finds. GLP-1 medications such as Ozempic and Wegovy may help lower the risk of certain cancers, a new study ...
In a study published Monday in the journal Annals of Internal Medicine, researchers tracked the medical records of more than 200,000 people who started medications to treat type 2 diabetes ...
SGLT2 inhibitors cause the loss of 60–100 grams (2.1–3.5 oz) glucose in the urine each day and are associated with a modest, sustained weight loss of 1.5–2 kilograms (3.3–4.4 lb) in people with type 2 diabetes. The weight loss is less than expected due to compensatory increases in energy intake, but is additive when combined with GLP-1 ...
GLP-1 agonists were initially developed for type 2 diabetes. The 2022 American Diabetes Association standards of medical care recommend GLP-1 agonists as a first line therapy for type 2 diabetes, specifically in patients with atherosclerotic cardiovascular disease or obesity. The drugs were also noted to reduce food intake and body weight ...